Litcius/Paper detail

Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa

Jocelyn Qi-Min Teo, Jie Chong Lim, Cheng Yee Tang, Shannon Jing-Yi Lee, Si Hui Tan, James Heng-Chiak Sim, Rick Twee‐Hee Ong, Andrea Lay‐Hoon Kwa

2021mSphere51 citationsDOIOpen Access PDF

Abstract

Pseudomonas aeruginosa infection is one of the most difficult health care-associated infections to treat due to the ability of the organism to acquire a multitude of resistance mechanisms and express the multidrug resistance phenotype. Ceftolozane/tazobactam (C/T), a novel β -lactam/ β -lactamase inhibitor combination, addresses an unmet medical need in patients with these multidrug-resistant P. aeruginosa infections.

Topics & Concepts

Pseudomonas aeruginosaMicrobiologyBiologyCeftazidime/avibactamGenotypeMultiple drug resistanceCeftazidimeDrug resistanceBacteriaGeneGeneticsAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyInfections and bacterial resistance
Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa | Litcius